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Abstract
Myeloproliferative disorders (MPDs) are heterogeneous diseases that occur at
the level of a multipotent hematopoietic stem cell. They are characterized by
increased blood cell production related to cytokine hypersensitivity and virtually
normal cell maturation. The molecular pathogenesis of the MPDs has been
poorly understood, except for chronic myeloid leukemia (CML), where the Bcr-
Abl fusion protein exhibits constitutive kinase activity. Since some rare MPDs
are also related to a dysregulated kinase activity, a similar mechanism was
thought to be likely responsible for the more frequent MPDs. We investigated the
mechanisms of endogenous erythroid colony formation (EEC) by polycythemia
vera (PV) erythroid progenitor cells and found that EEC formation was abolished
by a pharmacological inhibitor of JAK2 as well as an siRNA against JAK2. JAK2
sequencing revealed a unique mutation in the JH2 domain leading to a V617F
substitution in more than 80% of the PV samples. This mutation in the...
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Myeloproliferative disorders (MPDs) are heteroge-
neous diseases that occur at the level of a multipotent
hematopoietic stem cell. They are characterized by
increased blood cell production related to cytokine
hypersensitivity and virtually normal cell maturation.
The molecular pathogenesis of the MPDs has been
poorly understood, except for chronic myeloid leuke-
mia (CML), where the Bcr-Abl fusion protein exhibits
constitutive kinase activity. Since some rare MPDs
are also related to a dysregulated kinase activity, a
similar mechanism was thought to be likely respon-
sible for the more frequent MPDs. We investigated the
mechanisms of endogenous erythroid colony forma-
tion (EEC) by polycythemia vera (PV) erythroid
progenitor cells and found that EEC formation was
abolished by a pharmacological inhibitor of JAK2 as
well as an siRNA against JAK2. JAK2 sequencing
revealed a unique mutation in the JH2 domain leading
to a V617F substitution in more than 80% of the PV
samples. This mutation in the pseudokinase
autoinhibitory domain results in constitutive kinase
activity and induces cytokine hypersensitivity or
independence of factor-dependent cell lines.
Retroviral transduction of the mutant JAK2 into
murine HSC leads to the development of an MPD with
polycythemia. The same mutation was found in about
50% of patients with idiopathic myelofibrosis (IMF) and
30% of patients with essential thrombocythemia (ET).
Using different approaches, four other teams have
obtained similar results. The identification of the JAK2
mutation represents a major advance in our under-
standing of the molecular pathogenesis of MPDs that
will likely permit a new classification of these diseases
and the development of novel therapeutic approaches.
Polycythemia Vera and the Other MPDs
The myeloproliferative disorders (MPDs) were initially
thought to include four different diseases: chronic myeloid
leukemia (CML), polycythemia vera (PV), essential throm-
bocythemia (ET) and chronic idiopathic myelofibrosis
(IMF). Subsequently, hypereosinophilic syndrome (HES)
and chronic neutrophilic leukemia (CNL) were included in
the classification of MPDs. These disorders are hemato-
logical malignancies that arise from the transformation of a
multipotent hematopoietic stem cell. Clonal hematopoie-
sis is characteristic of CML, PV, IMF and, at least, some
cases of ET. Except for IMF, all MPDs are characterized by
increased levels of blood cell production with predomi-
nance of one myeloid cell lineage and no marked alter-
ations in cellular maturation. Each of the MPDs has a pro-
pensity to progress towards acute leukemia, yet they differ
with respect to the rate of transformation to blast crisis.
Many complications of the MPDs, such as thrombosis in
ET and PV, are related to the overproduction of mature
blood cells.
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Pathogenesis of MPDs
The initial classification of the MPDs was based on clini-
cal, morphological and biological criteria. After the dis-
covery of the Philadelphia chromosome (translocation
t:9;22) and the identification of the Bcr-Abl fusion pro-
tein, a new classification based on the Bcr-Abl molecular
marker was developed. Several lines of evidence established
that the constitutive Bcr-Abl kinase activity was at the ori-
gin of CML, as demonstrated by the successful cytoge-
netic response obtained in patients treated with imatinib
mesylate (Gleevec), an inhibitor of Kit, PDGFR and Abl
tyrosine kinase activities. Subsequently, a constitutive ty-
rosine kinase activity was also implicated in other MPDs
or related disorders: activating mutations in c-kit in sys-
temic mastocytosis (SM),1 chimeric FGFR1 transcripts in
some atypical form of CML2 and the FIP1L1-PDGFRA fu-
sion protein in a subpopulation of patients with HES.3
In most instances, the molecular pathogenesis of the
MPDs was identified by the examination of recurrent chro-
mosomal translocations (i.e., CML or atypical CML)4 or as
the consequence of a clinical response to tyrosine kinase
inhibitors.3 By contrast, recurrent chromosomal transloca-
tions were not found in patients with PV, ET and IMF. Nev-
ertheless, a clinical response to imatinib was described in
some PV patients, but it is not known whether this response
is due to an inhibition of Kit signaling.5
Hypersensitivity to Cytokines in PV
and Other MPDs
A constant hallmark of MPDs is an abnormal response to
cytokines. As early as 1974, it was demonstrated that a
subpopulation of late erythroid progenitors in PV could
proliferate in vitro in the absence of erythropoietin (Epo).6
This assay was subsequently used to distinguish primary
polycythemia from secondary forms of erythrocytosis. Nev-
ertheless, EEC formation is not specific for PV since it is
also seen in some ET, IMF and CML patients or in patients
suffering from thrombotic diseases, such as the Budd Chiari
syndrome but no evidence of an MPD. A small fraction of
erythroid progenitors in PV are truly Epo-independent, but
the major abnormality is hypersensitivity to numerous
growth factors including Epo, GM-CSF, IL-3, SCF and
IGF1.7,8 Similarly, megakaryocyte (MK) progenitors are
hypersensitive to thrombopoietin (Tpo) in ET and IMF.9
Numerous studies have ruled out autocrine stimulation or
a cytokine receptor defects as causes of the abnormal
cytokine response: EEC formation in PV was not blocked
by neutralizing anti-Epo antibodies; no significant Tpo
synthesis by MK was documented in ET and IMF; no quan-
titative EpoR defect was found in PV; no genomic muta-
tion in EpoR or c-mpl (TpoR) was seen in PV, ET and IMF.
Together, these results suggested that the cytokine hyper-
sensitivity was likely due to a downstream signaling de-
fect and that the Bcr-Abl negative MPDs (PV, ET and IMF)
were accompanied by a constitutive kinase activity. Alter-
natively, a mutation (activating or loss of function) in a
phosphatase gene, as illustrated by the juvenile myelo-
monocytic leukemia model,10 could also result in a similar
phenotype.
Among the three main subtypes of Bcr-Abl negative
MPDs, PV is certainly the most straightforward model to
utilize in order to define the underlying molecular patho-
genesis since cytokine-independent terminal erythroid dif-
ferentiation only depends on Epo signaling. In contrast,
the main abnormality in ET and IMF involves MK prolif-
eration and differentiation which are dependent upon not
only Tpo, but also other cytokine signaling events.
Epo/EpoR Signaling
Epo and the EpoR are crucial for mature red blood cells
formation. In the absence of Epo or EpoR, committed eryth-
roid progenitors undergo apoptosis at the CFU-E and pro-
erythroblast level.11 Equally important is the Janus kinase
JAK2 bound to EpoR and activated upon Epo binding to
the receptor.12 The knock out of JAK2 in mouse embryos is
lethal at embryonic day 12.5 due to the absence of mature
red cell formation in the fetal liver. Thus, Epo, EpoR and
JAK2 are absolutely required for red blood cell formation.
The number of EpoRs on the cell surface of erythroid pre-
cursor cells is low (typically 500-2000 receptors/cell) and
the EpoR has apparently evolved to be poorly expressed at
the cell surface. Thus, the EpoR must be efficiently acti-
vated by Epo in conditions where receptor numbers at the
cell surface are low. One strategy by which this may be
achieved is the ligand-independent dimerization of the
EpoR on the cell surface.13 Upon Epo binding, the dimer
conformation changes in such a way that a rotation in the
transmembrane and cytosolic juxtamembrane α-helix is
required to activate JAK214 (Figure 1; see Color Figures,
page 545). JAK2 is bound to the EpoR cytoplasmic do-
main in the absence of ligand activation. In fact, binding of
the N-terminus FERM domain of JAK2 to sequences en-
compassing Box1 and Box2 of the EpoR cytoplasmic do-
main is required for trafficking the EpoR to the cell surface.15
The presence of JAK2 promotes receptor trafficking to the
Golgi and acquisition of a mature glycosylation pattern.
Signaling by EpoR starts with JAK2 activation. Three
EpoR cytoplasmic hydrophobic residues located before
Box1 seem to be crucial for activating JAK2.14 These resi-
dues however are not required for the chaperone effect of
JAK2 on EpoR trafficking. Upon receptor activation, JAK2
becomes phosphorylated at the activation loop Y1007,
Y1008 and at many other Y residues, such as at Y570 (with
inhibitory effect) and at Y221 and Y813 (with positive
effects on signaling).16,17 JAK2 also phosphorylates the EpoR
cytoplasmic Y residues. All these p-Y residues in EpoR
and JAK2 become recruitment sites for STAT5, STAT3,
STAT1, SH-PTP1, CIS and shc/grb2. As a consequence,
EpoR signaling activates STAT, MAP-kinase, PI-3-kinase
and AKT. The biological consequences of this cascade of
events are survival, proliferation and differentiation of eryth-
roid progenitors.
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JAK2 as a Candidate Gene Involved in
PV Pathogenesis
Several lines of evidence suggested that JAK2 was the most
likely candidate gene involved in the pathogenesis of PV.
First, JAK2 is directly involved in the intracellular signal-
ing following the exposure to cytokines to which PV pro-
genitors display hypersensitivity (Epo, GM-CSF, IL-3,TPO
and more or less SCF and IGF-1). Second, spontaneous ac-
tivation of STAT3 was found in the granulocytes of 30% of
PV patients18 and an increased AKT phosphorylation was
observed in erythroid progenitors after cytokine stimula-
tion19 (Figure 1; see Color Figures, page 545). In erythro-
blasts derived from EEC, the anti-apoptotic mitochondrial
protein Bcl-xL regulated by Epo signaling through STAT5
activation was shown to be increased.20 Moreover, differ-
ent kinase inhibitors, including a JAK2 inhibitor are known
to block EEC formation.21 Similarly in IMF, spontaneous
MK growth was blocked by a STAT5 dominant negative.22
Third, JAK2 is involved in EpoR15 and Mpl23 trafficking
from the endoplasmic reticulum to the cell membrane, and
the processes involving Mpl trafficking/maturation are al-
tered in PV and IMF.24 Fourth, although not recurrent, a
common cytogenetic abnormality in PV is a gain in 9p
where the JAK2 gene is localized. In addition, loss of het-
erozygosity (LOH) of chromosome 9p was found in 30% of
PV patients identifying a large genomic region of DNA as
a target for the search for a potential candidate disease as-
sociated genetic defect.25
A Unique Acquired Clonal JAK2 Mutation Is
Found in PV, ET and IMF
A recurrent unique acquired clonal mutation in JAK2 was
recently found by five different research teams. This muta-
tion was observed in a majority of PV patients and a sig-
nificant proportion of patients with other MPDs, including
ET, IMF and some rare MPDs. Our group worked on the
mechanisms leading to EEC formation and identified JAK2
as a potential candidate gene because JAK2 kinase inhibi-
tors as well as a JAK2 siRNA inhibited EEC.26 Three other
teams sequenced JAK2 as a consequence of kinase gene
sequencing in MPDs.27-29 Finally, one team mapped the
minimal region on chromosome 9p to a 6.2 Mbp interval
that contains several genes including JAK2.30
A unique valine to phenylalanine substitution at posi-
tion 617 (V617F) in the pseudokinase JAK2 domain has
been identified. The incidence of this mutation in PV pa-
tients is very high (78% of 506 patients), ranging from
65% to 97% depending on the study. These variations in
percentage of patients involved is likely due to the clinical
criteria used for diagnosis, either the Polycythemia Study
Group (PSVG) or World Health Organization (WHO) clas-
sifications, and also the sensitivity of the assay used to
detect JAK2 V617F. The JAK2 V617F mutation was, how-
ever, not found in some patients who were shown to have
both monoclonal hematopoiesis and to form EEC, demon-
strating that some cases of true PV are related to other mo-
lecular defects (our own unpublished results). Sequencing
of genomic DNA from granulocytes was used in most stud-
ies to detect the mutation.26-30 The sensitivity of this tech-
nique is difficult to assess precisely, but it is likely that a
threshold of 5% to 15% cells harboring the mutation is
required for such an analysis to be positive. In one study,
the mutation was detected in 97% of the PV samples (71/
73) with a sensitive PCR assay.27 The variable prevalence
estimates of the JAK2 V617F in MPD patients therefore
may be related to the fact that in some patients with JAK2
V617F, less than 10% of granulocyte JAK2 alleles are JAK2
V617F alleles, suggesting that MPD patients could retain
normal stem cell clones. These data are surprising since PV
is considered to be a clonal disease with the majority of my-
eloid cells, including granulocytes, belonging to the clone.
Further studies are, therefore, required to confirm these data.
The JAK2 mutation is somatic and occurs at the level
of a hematopoietic stem cell. In all studies, the mutated
JAK2 was found in myeloid cells, i.e., bone marrow cells,
granulocytes, platelets and erythroblasts derived from
CD34+ cells, but not in T cells. In addition, mutant JAK2
was found in hematopoietic colonies derived from hemato-
poietic progenitor cells.27 In contrast, the mutation was not
present in non-hematopoietic cells in most patients.28,30
Since familial MPDs have been reported, it was important
to know if this mutation can be germ-line. Linkage analy-
sis did not show co-segregation with the 9p locus suggest-
ing that the V617F substitution occurred as a somatic mu-
tation even in these families. The similar frequency of the
V617F mutation in familial and sporadic PV is in favor of
this assumption31 (Najman, personal communication). In
one study, however, the mutation was detected in buccal
swabs of 4% of the patients.28 This finding may be due to
contamination by granulocytes because in another study
two patients positive for the mutation after analysis of buc-
cal swabs were negative in cells within hair follicles.30
The JAK2 V617F mutation has been found in other
Bcr-Abl negative MPDs with a frequency of about 50% in
IMF and more variably in ET (from 25% to 57%).26-28,30 In
many cases, the mutation was detected only at the thresh-
old of the sequencing technique in ET. This may signify
that hematopoiesis is not entirely clonal in many ET pa-
tients and that the mutation must be searched by more sen-
sitive techniques or directly in platelets. The JAK2 muta-
tion was recently found in other MPDs with a frequency of
about 20% in atypical CML and unclassified MDS and at a
lower frequency (2%-3%) in HES, CMML or SM.32 By con-
trast, the mutation was not detected in AML, except for
AML secondary to an MPD or megakaryocytic leuke-
mia.32,33 Thus, the presence of JAK2 V617F mutation pro-
vides a means of developing a new classification of MPDs
that includes the majority of PV cases, a large fraction of
cases of IMF and some cases of ET (the precise frequency
remains to be determined) and some atypical MPDs. This
mutation opens new avenues both for the diagnosis and
the classification of MPDs.
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Direct causative relationship between
this mutation and PV
JAK kinases are composed of four conserved domains which
include a N-terminal FERM domain required for interac-
tion with cytokine receptors, an SH2 domain followed by a
pseudokinase (JH2, from JAK-homology 2) and a C-termi-
nal kinase (JH1, from JAK homology 1) domain. The V617F
mutation is located in the JH2 pseudokinase domain of
JAK2, which is involved in inhibition of the kinase activ-
ity.34,35 Several point mutations in the JH2 domain, like
Y570F and E665K lead to constitutive JAK2 kinase activ-
ity.16,17,36 A model structure of JAK2 attributes an important
function to amino acid residues around position 618 in the
interaction between JH1 and JH2 and thus in the auto-in-
hibitory function of JH2.37 It is likely that the V617F sub-
stitution leads to a gain of function as confirmed by two
observations: when transfected into factor-dependent cell
lines, the mutant JAK2 is auto-phosphorylated and STAT5,
ERK/MAP kinase and PI3K/AKT are activated in the ab-
sence of any cytokines.26 As a result, factor-dependent cells
become hypersensitive to cytokine, with only a minority
of cells acquiring cytokine independence.26,28,30 The effects
of V617F JAK2 are even more striking in cell lines express-
ing the EpoR suggesting that this mutation has a more
dramatic effect on the Epo/EpoR signaling.26
A direct link between the JAK2 V617F mutation and
PV is suggested by at least three lines of evidence: i) the
mutation is found in all spontaneous erythroid colonies
cloned from the marrow or peripheral blood of PV patients;
ii) the mutation induces IGF-1 hypersensitivity in cell lines
and a defect in Mpl trafficking (unpublished observation)
and iii) introduction of a JAK2 V617F DNA into murine
HSC followed transplantation into recipient mice and he-
matopoietic reconstitution leads to erythrocytosis with sple-
nomegaly. In these mice, significant increases in granulo-
cyte or platelet counts were not initially observed.26
How does the JAK2 V617F mutant
induce EPO hypersensitivity?
At present, it is unknown whether the mutant JAK2 requires
a cytokine receptor to scaffold and signal or whether it
signals independently of receptor association. In JAK2-
deficient cells, the mutant JAK2 could initiate a signal
alone but it also transduces a signal from the EpoR upon
Epo addition,26 demonstrating that the mutant JAK2 binds
to the EpoR cytoplasmic domain and transduces a ligand-
dependent signal. Since both the mutant JAK2 and EpoR
are expressed normally at low levels, it is likely that the
mutant JAK2 uses and amplifies the signal normally trig-
gered by EpoR. In the same cells or in retrovirally trans-
duced Ba/F3 cells, the mutant JAK2 was able to promote
trafficking of the EpoR to the cell-surface, albeit at a lower
efficiency than a wild-type JAK2. Further experiments are
still required to establish whether the mutant JAK2 also pro-
motes down-regulation of activated EpoRs and whether the
lower enhancement of trafficking is not due to this effect.
Our model would predict that the mutant JAK2 binds
to EpoR while the receptor is in the endoplasmic compart-
ment, the Golgi apparatus and the cell-surface. This bind-
ing promotes EpoR maturation but may also lead to a novel
mechanism of cytokine receptor activation from the cyto-
plasmic domain (inside out signaling), which could occur
before the EpoR reaches the surface. Bound JAK2 V617F
would thus phosphorylate discrete tyrosine residues and
would be autophosphorylated. These events would attract
SH2-containing proteins to the EpoR-JAK2 complex and
continuously activate STAT5, MAP-kinase, PI-3-kinase and
AKT pathways (Figure 1; see Color Figures, page 545).
The dimeric conformation of the receptor might be switched
on by this intracellular-to-extracellular activation. Addi-
tional experiments are needed to explore the ligand-inde-
pendent EpoR tyrosine phosphorylation in cells that ex-
press the mutant JAK2. It remains possible that receptor
signaling and phosphorylation might not require the
“switch” residues of the cytoplasmic juxtamembrane do-
main, which are required for ligand-dependent activation
of JAK2.14
The present evidence suggests that the JAK2 V617F
binds to the cytoplasmic domain of the intracellular and
cell-surface EpoR and that this event promotes ligand-in-
dependent signaling. Since constitutively active EpoR mu-
tants have been shown to produce in vivo not only erythro-
cytosis but also thrombocytosis,38 it is tempting to specu-
late that the interaction between EpoR and the mutant JAK2
may contribute not only to the pathobiology of PV but
also to ET.
How does a single JAK2 mutation give rise to
different phenotypes and diseases?
These data raise the intriguing question of how a single
mutation might give rise to at least three different diseases
(PV, ET and IMF) and also to some other atypical MPDs.
Evidence from clinical, biological and pathology data in-
dicates that ET, PV and IMF are related disorders. The evo-
lution of ET to PV has been well documented, although
some authors have stated these ET patients have been falsely
diagnosed and represent in reality a forme fruste of PV.
About 15% of ET patients progress to myelofibrosis and
approximately 20% of PV progress to IMF (spent phase).39
The boundaries between IMF and ET are not well defined
during the so-called pre-fibrotic form of IMF.40 In addition,
biological features of PV, i.e., EEC, high PRV1 mRNA in
granulocytes are also found in ET and IMF,41 while dimin-
ished membrane expression of Mpl (TpoR) by platelets has
also been described in ET and IMF.24 Recent results suggest
that these criteria except Mpl expression correlate with the
JAK2 V617F mutation.
Three different events may explain how a single muta-
tion might give rise to different phenotypes: transforma-
tion of different hematopoietic stem cells/progenitor cells,
different genetic backgrounds and additional somatic mu-
tations. It is unlikely that PV, ET and IMF reflect the trans-
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formation of hematopoietic progenitors at different stages
of differentiation. Indeed, there are many similarities be-
tween the biological properties induced by Bcr-Abl and
V617F JAK2 abnormalities, both of which mimic cytokine
signaling. There is evidence that Bcr-Abl exclusively trans-
forms HSC and not later progenitor cells, because, in con-
trast to other oncogenes, it does not confer self-renewal
properties to hematopoietic progenitors.42 It is expected
that the situation will be identical for the mutant JAK2,
although it has been demonstrated that a constitutively
active JAK2 can cooperate with Kit signaling to enhance
self-renewal of multipotent progenitors.43 The absence of
the JAK2 mutation in T cells from PV does not rule out that
the transformation event can occur in an HSC. Indeed, this
observation is reminiscent of the situation in CML, where
Bcr-Abl is hardly detected in T cells. The possibility that a
spontaneously active JAK2 is deleterious to mature T cells
cannot, however, be excluded. Further studies are required
to directly demonstrate that the JAK2 mutation occurs at
the level of the HSC.
It seems likely that some as yet unknown factors might
modulate the activity of the mutant JAK2. The V617F sub-
stitution is a subtle mutation that only changes the basal
JAK2 activation, otherwise all the biological properties of
JAK2 are maintained including its binding to cytokine re-
ceptors. However, it is not known if the mutant JAK2 re-
quires receptor binding or spontaneously oligomerizes on
the membrane or in the cytosol to induce signaling. The
highly transforming TEL-JAK2 protein that has lost all the
regulatory and cytokine receptor elements of JAK2 induces
direct signaling by oligomerization. Thus, it seems likely
that slight changes in the V617F JAK2 kinase activity might
profoundly change the phenotype of the disease. In favor
of this hypothesis, the V617F mutation was found to be
homozygous in about 30% of the PV, which correlates with
the 9p LOH, which is due to a mitotic recombination and
leads to a duplication of the mutated allele with a deletion
of the normal allele.28,30 This implies that the cells homozy-
gous for the mutation have a clonal advantage over the
heterozygous and non-mutated cells.30 Usually, LOH is a
mechanism of oncogenesis by which tumor suppressor
genes are inactivated. To our knowledge, LOH has never
been associated with gain of function mutations. Thus, gene
dosage and the presence of a normal JAK2 may influence
the activity of the mutant. Indeed, normal JAK2 is capable
of inhibiting STAT5 activation induced by the mutant.
Furthermore, expression of normal JAK2 in a cell line made
factor-independent by the mutant restores cytokine depen-
dency.26 The competition between the two JAK2s, wild type
and mutated, is not directly due to inhibition of the mutant
since wild type JAK2 does not inhibit auto-phosphoryla-
tion of the mutant28 but may occur on their substrate(s) by
competing for cytokine receptor binding. One might hy-
pothesize that the level of kinase activity modulates the
phenotype of the disease. The level of kinase activity could
be modified by gene dosage, by polymorphisms of JAK2 or
by cooperating genetic events, such as changes in a phos-
phatase or a SOCS gene, which encode for proteins that
normally attenuate JAK2 signaling from cytokine recep-
tors. We hypothesize that a low kinase activity would lead
to ET, an intermediate level to PV and a very high level to
IMF. Alternatively, the phenotype of the disease may be
dependent on genetic events not related to the V617F JAK2
kinase activity. These different hypotheses can now be
tested both in patients and in animal models of MPD.
Conclusion
The discovery of the JAK2 V617F mutation is a major ad-
vance in enhancing our understanding of both the molecu-
lar pathogenesis and the clinical aspects of PV and several
other Bcr-Abl negative MPDs. This observation opens new
avenues for fundamental and clinical researches and has
direct implications for the diagnosis and classification of
MPDs. Research can now focus on MPDs that are negative
for the V617F mutation, which might constitute a distinc-
tive entity. Further work is also needed to determine how a
single mutation in JAK2 gives rise to three different dis-
eases. Moreover, the JAK2 V617F mutation offers a mo-
lecular target for new drug discovery.
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